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Abstract
Background: Serological safety is an integral part of  overall safety for blood banks.
Objectives: The aim of  the study was to determine the prevalence and specificities of  red blood cell alloimmunization in 
multi-transfused patients  with chronic kidney disease (CKD).
Methods: A cross-sectional case-control study carried out at the University of  Port Harcourt Teaching Hospital in which 186 
patients with CKD were enrolled consecutively, 124 had received multiple transfusions (more than one unit of  blood in one 
month, or at least 10 units within 3 months), while 62 had never been transfused. Antibody screen test was performed by the 
gel agglutination technique. RBC antibody identification was performed on the sera of  those that tested positive to antibody 
screening test.
Results: Out of  the 124 multi-transfused patients  (total of  789 transfusions), 4 (3.2%) were alloimmunised. The alloimmunised 
patients received a higher mean number of  17.5 ± 12 blood units, compared to 6 ± 6 units by the non-alloimmunised multi-trans-
fused patient (p= <0.001). Six clinically significant alloantibodies were identified with all of  the alloimmunised patients forming 
more than one antibody. Anti-E was detected in all alloimmunised patients.
Conclusion: The prevalence of  RBC alloimmunisation in multi-transfused CKD patients was 3.2% with anti-E being the most 
frequently identified antibody.
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Introduction
Blood transfusion is an integral part of  the management 
of  patients with chronic kidney disease (CKD) as severe 
anaemia is a feature of  the late stages1. Chronic Kidney 
disease (CKD) is defined either as kidney damage/injury 
for ≥ 3 months and/or glomerular filtration rate (GFR) 
< 60ml/min per 1.73m2 for ≥ 3 months with or without 
kidney damage. It is usually accompanied by features of  
uraemia, and a need for renal replacement therapy (which
includes haemodialysis and/or kidney transplant) in its 
later stages.2,3,4 Management of  renal anaemia include the 
use of  erythropoiesis-stimulating agents (ESAs), blood 
transfusion as well as replacement of  iron and other 
nutritional supplements. The decision to treat a patient 
with either an ESAs or blood transfusion is made on 
the threshold for transfusion. A high threshold includes 
a low haemoglobin level, usually less than 10g/dl or the 
presence of  cardiac decompensation.3,4 In severe anae-
mia, immediate management may be blood transfusion 
to correct the anaemia in the short term. However, blood 
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transfusion especially when given repeatedly may increase 
the risk of  red cell alloimmunization.5
Red cell alloimmunization, is a humoral immune response 
which occurs when antibodies bind to foreign red cell an-
tigens due to antigenic disparity between donor and re-
cipient.  Red cell alloimmunization may be induced by 
blood transfusion, pregnancy or organ transplantation. 
The consequences include delayed haemolytic transfusion 
reaction, difficulties in getting compatible blood for fu-
ture transfusions, and a delay or failure in getting a kidney 
transplant.6,7 The incidence of  red cell alloimmunization 
ranges between 1-6% in single-transfused and up to 30% 
in multi-transfused patients (e.g., sickle cell disease, thalas-
saemia, haematological malignancies and ESRD).8,9,10,11,12 
In Nigeria, where multiple ethnicities contribute to genet-
ic heterogeneity among the population, a wide variety of  
antibodies are encountered. A study in Northern Nigeria 
reported a red cell alloimmunization prevalence of  8.8% 
in multi-transfused patients with sickle cell anaemia.13
In the United States, irregular RBC alloantibodies have 
been linked to the majority of  fatal haemolytic transfu-
sion reactions reported to the Food and Drug Adminis-
tration (FDA), and are considered the second main cause 
of  transfusion–related deaths14. Further studies have 
shown that prospective organ transplant recipients who 
received blood transfusions have an increased chance of  
having a high panel- reactive antibodies (PRA) score of  
greater than 80% compared to those who have never re-
ceived blood transfusion. PRA is defined as the percent-
age of  human leukocyte antigen (HLA) antigens singly or 
in combination out of  a panel reacting with the patient’s 
serum and may reflect the percentage of  donors expected 
to react with the patient’s serum. This finding has been 
associated with a longer wait to find a compatible donor 
and have completely precluded transplantation in some 
patients.3,15
Pre-transfusion compatibility testing (PCT) in this en-
vironment does not include antibody screening and ti-
tration which determines the patient’s antibody status as 
well as the severity of  alloimmunization when present. 
Identification of  the offending antibody can prevent fur-
ther development of  red blood cell alloantibodies as the 
patient is subsequently transfused with blood units free 
of  the offending antigen.
Therefore, the main objective of  this study was to as-
sess the prevalence of  red blood cell allommunization in 





The study population consisted of  186 adult patients with 
chronic kidney disease defined by patients who have GFR 
<60ml/min/1.73m2 for ≥ 3 months1, calculated using the 
modified diet in renal disease (MDRD) formula who had 
received multiple blood transfusions (more than one of  
blood within one month or at least 10 units of  blood 
within 3 months), and adult patients with chronic kidney 
disease who had no history of  blood transfusion. The 
study population were recruited consecutively from the 
nephrology out-patient clinic, medical outpatient clinics, 
as well as medical inpatients in UPTH.
Ethical approval was obtained from the hospitals’ Ethics 
Committee and written consent was obtained from every 
patient before recruitment into the study. All the patients 
were routinely screened for HIV.
Inclusion criteria for the cases: Patients with CKD who 
were eighteen years and above; who had received multiple 
transfusions (more than one unit of  whole blood within 
one month or at least 10 units of  whole blood within 3 
months).
Exclusion criteria for the cases: Patients with chronic 
kidney disease who were HIV positive and those with a 
history of  kidney transplant.
Inclusion criteria for the controls: Patients with chron-
ic kidney disease who were eighteen years and above; who 
have never been transfused.
Exclusion criteria for the control population: Patients 
with chronic kidney disease who had had a kidney trans-
plant; and those who were HIV positive.
Sample analysis: Two milliliters of  venous blood was 
collected into plain Vacutainer® bottles for Antibody 
screening, Antibody identification and titer determina-
tion. The serum was separated and stored in the freezer at 
-200C and analyzed weekly. The stored sera were thawed 
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and used for antibody screening by gel technology us-
ing commercially made panel of  cells – “ID-Diacell I-II-
III®” lot number 45184.91.x for antibody screening and 
set of  11 “ID-DiaPanel®” Lot number 45161.40.x for 
antibody identification manufactured by Diamed GmbH, 
Pra Rond 23, 1785 Cressier FR, Switzerland.
Antibody screening: Antibody screening test was per-
formed  on all study participants. Antibody screening test 
is not routinely done at UPTH as part of  pre-transfusion 
testing. . The recipient’s serum was combined with group 
O reagent red cells to allow for  antigen/antibody inter-
action in the upper chamber of  the microtube containing
antiglobulin and low ionic strength saline (LISS) reagent. 
They were incubated at 370C.  The gel card method is 
based on the principle of  differential passage of  agglu-
tinated and free red cells through a dextran-acrylamide 
gel microtube column during controlled centrifugation. 
Agglutinated red cells become trapped in or above the 
gel. Unagglutinated red cells travel through the gel parti-
cles and form a pellet at the bottom of  the microtube as 
shown in figure 117.
Three panel of  reagent red cells were used for antibody 
screening, and the antigenic specificity of  the reagent red 
cells used included Rh (D,C,E,c,e,Cw); Kell (K,k,Kpa,kp-
b,Jsa,Jsb); Duffy (Fya, Fyb); kidd (Jka,Jkb); Lewis (Lea,-
Leb); P (P1); MNS (M,N,S,s); Lutheran (Lua,Lub); and 
Xg
(Xga).
Red cell antibody identification was done using an anti-
gram provided by the manufacturer. Eleven panel of  re-
agent red cells were used for antibody screening with the 
above antigenic specificity.18 
Antibody titration: Eleven tests tubes were labelled ac-
cording to the serum dilutions: 1, 2, 4, 16, 32, 64, 128, 
256, 512, 1024 and 2048. After preparing the master dilu-
tions, titration was done using the gel cards following the 
same procedure above.19   To each of  the gel card column, 
50µL of  well mixed reagent cells (for which the patients’ 
serum tested positive during the antibody screening) was 
added. This was followed by 25µL of  diluted serum sam-
ple. Incubation was done at 370C and the gel cards were 
thereafter read using the Banjo® reader 
Statistical analysis: The statistical package SPSS (Sta-
tistical Package for Social Sciences) software version 20 
was used for data entry and analysis. Data was summa-
rized by appropriate statistical tools such as mean, medi-
an, standard deviation; frequencies and proportion. The 
statistical significance was tested using the chi square and 
Fisher’s test. P values less than or equal to 0.05 were con-
sidered as statistically significant. 
 
Results 
A total of  186 patients with chronic kidney disease par-
ticipated in the study. They comprised of  124 patients 
with history of  multiple blood transfusions and sixty-two 
(62) patients without a history of  blood transfusion. The 
cases and controls were well-matched for sex and age as 
shown in table 1. 







MALE (n/%) FEMALE (n/%) MALE (n/%) FEMALE (n/%)
<20 5(7.4) 0 0 0
20-29 7 (10.3) 9 (16.1) 2 (5.3) 3 (12.5)
30-39 6 (8.8) 15(26.8) 7 (18.4) 5 (20.8)
40-49 20 (29.4) 7 (12.5) 14 (36.8) 9 (37.5)
50-59 14(20.5) 13 9 (23.2) 2 (5.3) 3 (12.5)
>60 16(23.5) 12 (21.4) 13(34.3) 4 (16.6)
Total 68 (100) 56 (100) 38 (100.0) 24 (100.0)
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Among the multi-transfused patients, the mean serum 
creatinine and urea were 906.2 ± 631.2 mmol/l and 28 
± 9.8 mmol/l respectively compared to 608.9 ± 392.9 
mmol/l and 20.4 ± 12.4mmol/l respectively for the con-
trols. The differences in creatinine and urea in the subjects 
and controls were not statistically significant as shown in 
table 2. The mean estimated GFR for the subjects was 
24 mls/min/1.73 m2 compared to 62 mls/minute/1.73 
m2 for the controls. This value was statistically significant 
(p-value <0.005). 
Seven hundred and eight-nine [789] units of  blood were 
received by the multi-transfused patients. The number of  
units transfused per patient ranged from 2 to 34 with a 
mean and standard deviation of  6 ± 6 units. 
Prevalence of  red cell alloimmunization: Antibody 
screening was positive in five of  the multi-transfused 
CKD patients. None of  the controls had a positive an-
tibody screen. Alloantibodies were identified in four of  
the multi-transfused patients and one of  them had an au-
toantibody. 
TABLE 2: Baseline characteristics of patients with chronic kidney disease.





WEIGHT (KG) 68.7 ± 14.5 77.8 ± 12.5 0.112
HEIGHT (CM) 170.8 ± 12 171.2 ± 13 0.904
Creatinine (μmol/L) 906.2 ± 631.2 608.9 ± 392.9 <0.0001*
Urea (mmol/L) 28 ± 9.8 20.4 ± 12.4 <0.0001*
eGFR (mls/mins/1.73m2) 24 26 <0.0001*
eGFR: estimated glomerular filtration rate.
Values are expressed as mean ± SD
*Indicates difference is statistically significant (p<0.05)
The alloimmunized multi-transfused patients had a high-
er mean number of  units transfused (17.5 ± 12 units) 
compared to the non-alloimmunized multi-transfused 
patients which had a mean of  6 ± 6 units, and this was 
statistically significant (p= 0.001). 
Among the subjects, females had a higher alloimmuni-
zation rate of  2.4% (n = 3) compared to the males 0.8% 
(n=1). Females were 2.2 times more likely to develop al-
loantibodies than the males, however this association was 
not significant (odds ratio = 2.2, 95% Confidence Inter-
val = 0.193-26.154. Of  the 3 females who were alloim-
munised, one was nulliparous while the other two were 
multiparous. 
Frequency, specificity and titre of  red cell alloanti-
bodies: A total of  6 alloantibodies were detected in the 
alloimmunised, three patients developed double alloan-
tibodies while one developed triple alloantibodies [table 
3]. Anti E was detected in all four multi-transfused allo-
immunised patients while the other antibodies detected 
were anti Jka, anti C, anti D, anti Fya and anti M respec-
tively [table 3]. 
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Table 3: Characteristics of alloimmunized multi-transfused chronic kidney disease patients.








Male 9 2 Anti-Jka, Anti-E 
2 38 
Female 10 2 Anti E Anti- Fya
3 32 
Female 34 2 Anti-E Anti-M 
4 22 
Female 17 3 Anti-C 
Anti-E 
Anti-D 
Figure 1: Antibody screening using the gel card
The frequency of  anti E among the multi-transfused 
ESRD patients was 3.2% while the other antibodies each 
showed frequency of  0.8% each as shown in figure 2. 
Two of  them had a titre of  1024 while the others had 
titres of  512 and 32 respectively. The multi-transfused pa-
tients with the highest titre developed antibodies to anti 
E, anti- M and anti Fy.a  
The risk of  alloimmunization per unit of  blood, defined19 
as the total number of  alloantibodies detected (6), divided 
by the total number of  transfused units (789) multiplied 
by 100, was 0.76% for the multi-transfused CKD patients. 
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Figure 2: Prevalence of alloantibodies among multi-transfused chronic kidney disease patients
Anti E Anti Fya Anti Jka Anti M Anti C Anti D















Blood transfusion may be life-saving in chronic kidney 
disease (CKD) as it promptly improves the oxygen-car-
rying capacity in patients with symptomatic anaemia. 
However, transfusion-transmissible infections (TTI) and 
alloimmunisation are potential complications especially in 
multi-transfused patients. In our study, there were more 
males with CKD compared to females similar to the find-
ings of  iseki et al.20 
The prevalence of  red cell alloimmunization among 
multi-transfused patients with CKD in this study was 
3.2%. None of  the controls had alloantibodies. This 
prevalence is lower than that reported by shuklla et al21 
(9.8%) and Babiker et al22 (13.1%). The difference could 
be due to varied geographical locations of  the studies 
as prevalence of  antigens varies with geographical lo-
cations.23 A higher prevalence may also have been seen 
in this study if  serial antibody screening test were done 
on these study participants. Red blood cell non-ABO 
blood group alloantibodies has been shown to evanes-
cence over time confounding compatibility testing and 
predisposing patients to delayed haemolytic transfusion 
reactions.23 The mean number of  blood units transfused 
in this study was significantly higher in individuals that 
developed RBC alloantibodies. This might be because the 
multi-transfused patients were exposed to more donors 
with different genetic makeup. Natukunda et al12 and San-
tos et al24 also reported higher prevalence of  alloantibody 
formation in recipients who received the more transfu-
sions. The mean number of  blood units received by the 
cases was 17.5 ±12, which is in concordance with reports 
that multi-transfused patients who developed received 16 
to 25 units of  blood.24,25 The risk of  alloimmunization 
in this study was 0.76%, and this is within the reported 
range of  0.5 to 5.9% seen in the literature.24,25,26 
In our study, the rate of  alloimmunization was not sig-
nificantly influenced by sex which is contrary to what was 
reported by Babiker et al,27 Silvia et al28 and Zaman et al29 
who found a higher prevalence in women, but similar to 
the findings of  Shukla et al.30 We also observed that all 
the alloimmunised patients developed multiple antibodies 
contrary to the findings of  Skulla30. This may be attribut-
ed to genetic differences, and lack of  routine pretransfu-
sion antibody screening test in this environment which 
increases the tendency to develop an additional alloanti-
body after subsequent transfusions. 
In concordance with other studies, the most frequent red 
cell antibodies in our study were against the E antigen 
(figure 2) of  the Rh blood group system.31,32,33 The fre-
quency of  the E antigen is generally low in blacks (about 
21%), as such multi-transfused patients who were hith-
erto lacking the E antigen are likely to develop anti-E 
from transfusions.34 In addition, anti-E has been found 
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to be the commonest alloantibody during routine screen-
ing and this is probably because half  the anti-E are weak, 
naturally occurring Ig M antibodies35. A study in Kano, 
Nigeria showed a low distribution of  Rh E (34%), which 
further suggests a higher likelihood of  recipients devel-
oping alloantibodies to it.36 
The other identified antibodies which showed the least 
combination were anti-M, anti-Jka and anti-Fya and this 
is similar to other reports.37 Anti M is a naturally occur-
ring cold antibody and is often not reactive at 370C and 
with anti-human globulin [AHG] reagent, except when 
present in very high titre.38 However, a small percentage 
of  anti-M is of  the immune type and can elicit haemo-
lytic transfusion reactions.39 Studies show that two-thirds 
or more of  blacks are negative for Duffy antigen Fy (a-
b-), and in Nigeria, the prevalence of  anti-Fya is about 
4.3%.39 Similarly, the prevalence of  anti JKa was reported 
as 4.9% in Nigeria.40 
The highest antibody titre observed in this study was 
1024 while the least was 4. One of  the multi-transfused 
patients developed an autoantibody and this can lead to 
shortened red cell life span, predisposing the patient to 
further transfusions28. One of  the multi-transfused pa-
tients that was Rh D positive, developed antibodies to the 
Rh D antigen. This suggests that this patient might have 
had a partial D. Persons of  African origin have been re-
ported to show the presence of  numerous Rh variants.41,42 
In addition, patients in this environment are not usually 
phenotyped for the partial-D variant; hence there may be 
a propensity to develop antibodies to the Rh D antigen.  
Studies have shown that HLA alloimmunization is asso-
ciated with RBC antibodies in multiply transfused sick-
le cell patients. This may result in graft rejection during 
stem cell or organ transplantation.43
Conclusion 
This study showed that 3.2% of  the multi-transfused pa-
tients with CKD developed alloantibodies most of  which 
were of  the Rh phenotype. These alloantibodies may lead 
to allograft rejection, or even poor patient survival. Thus 
we advocate that renal transplant be instituted at the ear-
liest opportunity whenever it becomes inevitable as a mo-
dality of  treatment to enhance better outcomes.
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